AlloMap Molecular Expression Testing

New from XDx – Announcing…

AlloMap molecular expression testing is now available for cardiac transplants as early as 2 months post cardiac transplant!

For cardiac transplant patients, acute cellular rejection is most worrisome in the first months post transplant. As of Monday, August 21, 2006, AlloMap molecular expression testing is available to help you monitor patients as early as 2 months post cardiac transplant. When combined with patient assessment, AlloMap testing can provide the confidence you need to rule out acute cellular rejection.

Freedom from Future Rejection

A CARGO sub-study showed that patients with scores < 20 in the first 6 months post transplant were free from ACR ≥ 3A(2R) for the next 80 days (~12 weeks)¹.

¹ Data on File

Transplant Clinic

Patients & Families

Lab Professionals

Discover XDx

Patients & Family

Font Size:

	The AlloMap Testing Process
	Patient Service Centers
	Health Insurance
	Terms To Know
	FAQ

The AlloMap Testing Process

XDx works with transplant clinics to make AlloMap testing available to their patients. When AlloMap testing is available at your transplant clinic, your physician can decide whether to order AlloMap testing for you. Currently, AlloMap testing is available for heart transplant recipients (at least 15 years old) who have had a transplant at least six months ago.

Once your doctor orders AlloMap testing and completes the AlloMap test requisition form, the following steps occur: (Place your mouse over each section for more details.) After testing is complete, in most circumstances, XDx bills your insurer directly. Click here for more information on billing and reimbursement.

AlloMap testing process